Bio-Rad's Q2 revenue drops

By LabPulse.com staff writers

July 31, 2020 -- Bio-Rad Laboratories reported that the COVID-19 pandemic negatively impacted its revenue for the second quarter (end-June 30) as well as for the first half of the year.

Sales dropped 6.2% to $536.9 million compared with $572.6 million for the second quarter of 2019. In particular, revenues in the company's clinical diagnostics segment decreased by 20.7%.

However, net income for Q2 was $966.4 million versus $598.8 million in the second quarter of 2019 primarily due to the recognition of changes in the fair market value of equity securities related to the holdings of Bio-Rad Laboratories' investment in Sartorius.

Year-to-date net income reached $1.65 billion compared with $1.46 billion for the same period last year. Given the situation with the pandemic, the firm thinks its third quarter 2020 year-over-year currency-neutral sales may be flat to up 5%.

BioRad teams with Biodesix on COVID-19 total antibody test
Bio-Rad Laboratories and lung cancer diagnostics firm Biodesix have joined forces to launch a serology test for detecting COVID-19 antibodies.
Bio-Rad COVID-19 test cleared in U.S.
Bio-Rad Laboratories has garnered emergency use authorization from the U.S. Food and Drug Administration for its droplet digital polymerase chain reaction...

Copyright © 2020 LabPulse.com

Last Updated ls 7/31/2020 4:57:37 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current